Some links on our site may earn us a commission at no extra cost to you. Learn more.
Published July 12, 2026. Updated October 10, 2026. Prices and specs checked August 19, 2026.
Medical disclaimer: We are not doctors or medical professionals, and this comparison is not medical advice. GLP-1 medications are prescription drugs that require evaluation by a licensed healthcare provider and are not appropriate for everyone. Consult a qualified clinician before starting any medication or weight loss program.
Hims vs SkinnyRx is really a comparison of brand-name and compounded GLP-1 programs, and the fact that gets blurred most often is regulatory. Only brand-name Wegovy and Zepbound are FDA-approved. Compounded semaglutide and tirzepatide, the entire SkinnyRx lineup, are not, and the FDA’s own guidance says so directly. That distinction matters more than price or format when deciding which side fits a given buyer.
Hims vs SkinnyRx: what does each cost per month?
Neither platform’s headline price is the whole bill. The table breaks each monthly cost into membership or consultation, medication and shipping, as published on each program’s own site and checked in August 2026.
| Program & Tier | Membership / Consultation | Medication | Shipping | Total Monthly (uninsured) |
|---|---|---|---|---|
| Hims — Wegovy pen, self-pay | $149/mo (after a $39 first month) | Starting at $199/mo, billed separately | Not separately itemized | ~$348/mo and up |
| Hims — insured + NovoCare savings card | $149/mo membership still applies | As low as $25/mo for eligible commercially insured patients | Not separately itemized | ~$174/mo and up |
| SkinnyRx — compounded semaglutide (injectable/sublingual) | Included, no separate fee | $199/mo | Free overnight | $199/mo |
| SkinnyRx — compounded semaglutide (tablets) | Included, no separate fee | $249/mo | Free overnight | $249/mo |
| SkinnyRx — compounded tirzepatide | Included, no separate fee | $299/mo | Free overnight | $299/mo |
Hims figures come from the Wegovy pen and membership pages at hims.com, and the insured figure from Novo Nordisk’s NovoCare Wegovy savings offer page, both checked October 10, 2026. SkinnyRx figures come from SkinnyRx’s own published pricing, checked August 2026.
Assume the standard once-weekly injection schedule most GLP-1 prescribers use. The uninsured Hims total then works out to roughly $80 a week, and the SkinnyRx injectable tier to about $46 a week ($348 and $199, each divided by 4.33 weeks a month). Dose increases typically raise the medication line. Sublingual and tablet formats may follow a different cadence set by the prescribing clinician, so treat the weekly figure as an injectable-to-injectable comparison only.
Prices are approximate, current as of publication, and change frequently — confirm the latest price with the provider before enrolling.
Hims vs SkinnyRx: how do they score on four criteria?
Marketing language on both sides blurs these lines, so it helps to be precise about what separates a brand-name GLP-1 program from a compounded one.
- Regulatory status. Whether the medication went through FDA premarket review, or is a compounded formulation that hasn’t.
- Active ingredient sourcing. Whether the semaglutide or tirzepatide comes through the branded manufacturer’s FDA-inspected supply chain, or from a compounding pharmacy formulating it to a prescription.
- Monthly cost, itemized. The consultation or membership fee, the medication charge and shipping, itemized so nothing hides inside a bundle.
- Medical oversight model. How much clinical contact patients get, from intake-only messaging to something closer to ongoing monitoring.
How do Hims and SkinnyRx differ on regulatory status?
Regulatory status: Hims dispenses the Wegovy pen and Wegovy pill, both FDA-approved semaglutide formulations. SkinnyRx’s semaglutide and tirzepatide are compounded. A compounding pharmacy formulates them rather than manufacturing and approving a finished drug product.
The FDA’s shortage declarations had allowed broader compounding under Sections 503A and 503B. Both have ended: the FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage on February 21, 2025. Semaglutide’s grace periods closed in April and May 2025, and tirzepatide’s in March 2025. After that, large-scale compounding of essentially-copy versions became restricted to cases with documented patient-specific need.
How do Hims and SkinnyRx differ on sourcing and oversight?
Active ingredient sourcing: Hims’ brand-name pathway runs through Novo Nordisk’s own FDA-inspected manufacturing. SkinnyRx sources its active ingredient through licensed U.S. compounding pharmacies and ships from what it describes as FDA-regulated pharmacies. That is a real regulatory category, since pharmacies are FDA-registered and state-licensed. It is distinct from the drug product itself carrying FDA approval.
Monthly cost: broken out in full in the table above.
Medical oversight model: both platforms run on asynchronous telehealth. That means an online intake reviewed by a licensed prescriber, with ongoing contact through messaging rather than scheduled visits or lab work. Neither is built for complex medical histories. Both are designed for straightforward cases where the intake form covers what a prescriber needs to know.
Hims vs SkinnyRx: is compounded GLP-1 FDA-approved?
“Not FDA-approved” doesn’t mean illegal or automatically unsafe. Compounding is a legal, regulated practice, and the pharmacies compounding these drugs are FDA-registered and state-licensed. It does mean the finished product hasn’t gone through the FDA’s own review of a specific formulation’s safety, effectiveness and manufacturing consistency. That review is what “FDA-approved” certifies.
In February 2026 the FDA sent a warning letter to Lean Rx, Inc., dba SkinnyRx, over specific marketing language. That language included claims that its product contained “the same active ingredient as name-brand GLP-1 medications” and “the same active ingredient as FDA-approved medications.” The agency said those claims falsely implied FDA approval the compounded product doesn’t have. The FDA also flagged SkinnyRx’s own name appearing on product labels when SkinnyRx was not the actual compounder.
This was a labeling and marketing violation, not a finding about manufacturing safety. It is still a direct, on-the-record example of the line this criterion is about. Physicians have raised similar concerns more broadly. A Stanford Medicine report describes clinician worries about inconsistent dosing and sourcing across compounding pharmacies industry-wide, not specific to any one program.
Where does insurance change the Hims vs SkinnyRx price?
Hims’ own self-pay pricing starts at $199 a month for the medication. Novo Nordisk’s NovoCare Wegovy savings offer page says patients with qualifying commercial insurance can pay as little as $25 a month.
That makes insurance status the single biggest swing factor in this comparison. A compounded program can’t currently match a $25 insured price. But a self-pay patient comparing $348+ a month against SkinnyRx’s $199–$299 a month sees compounded medication as the cheaper option before the regulatory question is weighed in.
What fine print should you read before checkout?
Hims’ membership bills separately from medication, auto-renews and does not guarantee a prescription. Factor in the $149 a month even for a month a prescriber declines to renew a script. SkinnyRx bundles the consultation into its flat monthly price and carries no membership fee. Read the billing terms on each program’s own checkout page before entering payment information, on either platform.
Who does each approach fit?
Someone who wants an FDA-approved formulation, and can access commercial insurance plus a manufacturer savings card, fits the brand-name path best. At that combination the price beats every compounded option here. Someone paying entirely out of pocket, wanting a needle-free format, or prioritizing the lowest verified monthly number fits a compounded program best. They should first read and accept what “not FDA-approved” means for the specific product they would take.
Neither profile fits someone who hasn’t yet had the one conversation that matters. That conversation is with a licensed healthcare provider, about whether a GLP-1 medication is appropriate for their health history at all.
How was this GLP-1 comparison researched?
Every price and regulatory claim above was checked in August 2026 against each program’s own published pricing pages and the FDA’s own guidance and warning-letter record on compounded GLP-1 medications. This is a cost and regulatory-status comparison, not a clinical review. Read more about how we source and vet claims on our editorial standards page.
Related GLP-1 Comparisons
- Shopping the wider field? Our four-program audit of TrimRX, Brightmeds, Wellorithm, and AltRx checks prescriber licensing and pharmacy transparency across each one.
- For the full itemized year-one math on compounded versus brand-name, see the GLP-1 monthly bill, itemized.
Wegovy®, Ozempic®, Zepbound®, and Mounjaro® are trademarks of their respective owners, which are not affiliated with this site. One market note: Eden, another frequently searched program, paused new-patient GLP-1 enrollment as of mid-2026.
Hims vs SkinnyRx: common questions
Is compounded semaglutide or tirzepatide FDA-approved?
No. Only the brand-name products go through the FDA’s premarket review process: Novo Nordisk’s Wegovy and Ozempic, and Eli Lilly’s Zepbound and Mounjaro. Compounded versions, including everything SkinnyRx sells, are not FDA-approved. The FDA’s own guidance states directly that compounded drugs are not approved by the FDA.
How much does a Hims GLP-1 prescription cost per month?
After the $39 first month, the Hims Weight Loss Membership renews at $149/month, billed separately from medication. Hims lists the Wegovy pen starting at $199/month for eligible self-pay patients. That puts an uninsured floor around $348/month before any dose increase. Commercially insured patients combining coverage with Novo Nordisk’s savings card can pay as little as $25/month for the medication itself.
What does SkinnyRx charge each month?
SkinnyRx publishes three tiers. Compounded semaglutide injectable or sublingual costs $199/month, semaglutide tablets cost $249/month, and compounded tirzepatide costs $299/month. Each includes the consultation and free overnight shipping, with no separate membership fee.
Why did the FDA send SkinnyRx’s operator a warning letter?
In February 2026 the FDA sent a warning letter to Lean Rx, Inc., dba SkinnyRx, over marketing language. That language included claims implying the same active ingredient as FDA-approved brand-name drugs. The agency said it blurred the line around a product that is not itself FDA-approved. The FDA described it as a labeling-claims issue, not a manufacturing-safety finding.
Do I need to see a doctor before starting either program?
Yes. Both platforms use asynchronous telehealth intake reviewed by a licensed prescriber. Neither replaces a conversation with your own healthcare provider about whether a GLP-1 medication is appropriate for your health history. This article is not medical advice.
